Document Detail


Sildenafil citrate (viagra) induces cardioprotective effects after ischemia/reperfusion injury in infant rabbits.
MedLine Citation:
PMID:  15531735     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Infants undergoing surgery for congenital heart disease are at risk for myocardial ischemia during cardiopulmonary bypass, circulatory arrest, or low-flow states. The purpose of this study was to demonstrate the effects of sildenafil, a selective phosphodiesterase-5 (PDE-5) inhibitor on myocardial functional improvement and infarct size reduction during ischemia/reperfusion injury in infant rabbits. Infant rabbits (aged 8 wk) were treated with sildenafil citrate (0.7 mg/kg i.v.) or normal saline 30 min before sustained ischemia for 30 min and reperfusion for 3 h. Transesophageal echocardiography (TEE) was used to assess left ventricular cardiac output (LVCO) and aortic velocity time integral (VTI). After ischemia/reperfusion, risk area was demarcated by Evan's blue dye and infarct size determined by computer morphometry of triphenyltetrazolium chloride-stained sections. The sildenafil-treated group had preservation and elevation in LVCO (143% of baseline, p < 0.05) and an elevated aortic VTI (145% of baseline, p < 0.05) after 30 min of ischemia compared with the control group LVCO (72% of baseline, p < 0.05) and aortic VTI (73% of baseline, p < 0.05). This is a statistically significant increase in LVCO and aortic VTI in the sildenafil group compared with controls (n = 6/group, p < 0.05). The sildenafil-treated group had significant reduction in infarct size (15.5 +/- 1.2 versus 33 +/- 2.3 in the saline group, % risk area, mean +/- SEM, n = 10-15/group, p < 0.05). For the first time, we have shown that sildenafil citrate promotes myocardial protection in infant rabbits as evidenced by postischemic preservation and elevation in LVCO and aortic VTI and reduction in infarct size.
Authors:
Yvonne A Bremer; Fadi Salloum; Ramzi Ockaili; Eric Chou; William B Moskowitz; Rakesh C Kukreja
Related Documents :
11052925 - Characterization of an in vitro model for the study of the short and prolonged effects ...
20047685 - Apyrase treatment of myocardial infarction according to a clinically applicable protoco...
9436735 - Natural history of the spontaneous reperfusion of human cerebral infarcts as assessed b...
9594845 - Cardioprotection by local heating: improved myocardial salvage after ischemia and reper...
15157565 - The role and assessment of ventricular peptides in heart failure.
18451655 - Endovascular procedures.
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.     Date:  2004-11-05
Journal Detail:
Title:  Pediatric research     Volume:  57     ISSN:  0031-3998     ISO Abbreviation:  Pediatr. Res.     Publication Date:  2005 Jan 
Date Detail:
Created Date:  2005-01-04     Completed Date:  2005-05-12     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0100714     Medline TA:  Pediatr Res     Country:  United States    
Other Details:
Languages:  eng     Pagination:  22-7     Citation Subset:  IM    
Affiliation:
Division of Pediatric Cardiology, Department of Pediatrics, Virginia Commonwealth University Health System, Richmond, VA 23298, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
3',5'-Cyclic-GMP Phosphodiesterases
Animals
Aorta / pathology
Cardiac Output
Cyclic Nucleotide Phosphodiesterases, Type 5
Echocardiography / methods
Evans Blue / pharmacology
Heart / drug effects*
Hemodynamics / drug effects
Male
Myocardial Infarction / prevention & control
Myocardial Ischemia / drug therapy
Phosphodiesterase Inhibitors / pharmacology
Phosphoric Diester Hydrolases / metabolism
Piperazines / pharmacology*
Purines
Rabbits
Reperfusion Injury / drug therapy*
Sulfones
Time Factors
Vasodilator Agents / pharmacology
Ventricular Function, Left
Grant Support
ID/Acronym/Agency:
HL 51045/HL/NHLBI NIH HHS; HL-59469/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Phosphodiesterase Inhibitors; 0/Piperazines; 0/Purines; 0/Sulfones; 0/Vasodilator Agents; 139755-83-2/sildenafil; 314-13-6/Evans Blue; EC 3.1.4.-/Phosphoric Diester Hydrolases; EC 3.1.4.35/3',5'-Cyclic-GMP Phosphodiesterases; EC 3.1.4.35/Cyclic Nucleotide Phosphodiesterases, Type 5

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Adrenomedullin is highly expressed in blood monocytes associated with acute Kawasaki disease: a micr...
Next Document:  Thymic function and impaired maintenance of peripheral T cell populations in children with congenita...